Phenotypes Associated with This Genotype

Genotype
MGI:5506798

• Allelic Composition: Tg(MMTV-rtTA)1Lach/0; Tg(TetO-Erbb2)1Lach/0
• Genetic Background: involves: FVB

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased mammary adenocarcinoma incidence ( J:81083 )

• mice treated with doxycycline for 21 days develop invasive mammary carcinomas

• chronic treatment with doxycycline results in rapid development of multiple mammary tumors with 100% penetrance and a latency of 6 weeks

• mammary tumors are invasive solid nodular carcinomas

• withdrawal of doxycycline from chronically induced mutants results in full regression of tumors to a nonpalpable state in 94% of mice; a decrease in cell proliferation and increase in cell apoptosis is seen during regression

• mice in which doxycycline withdrawal leads to complete regression of tumors show tumor recurrence in the absence of doxycycline after an average of 153 +/- 93 days off doxycycline

increased metastatic potential ( J:81083 )

• some mutants treated with doxycycline develop pulmonary metastases (solid pulmonary nodules on the pleural surface); these mice show hunched posture, ruffled fur, labored breathing and die within one week

• pulmonary metastases have features of mammary epithelial carcinomas

• withdrawal of doxycycline from chronically induced mutants with pulmonary metastasis results in regression of primary mammary tumors and resolution of the respiratory phenotype

mortality/aging

premature death ( J:81083 )

• mice that develop pulmonary metastases following chronic doxycycline treatment die within one week of developing a hunched posture and labored breathing

endocrine/exocrine glands

mammary gland duct hyperplasia ( J:81083 )

• mice treated with doxycycline for 4 days exhibit hyperplastic abnormalities in the mammary ductal trees

increased mammary adenocarcinoma incidence ( J:81083 )

• mice treated with doxycycline for 21 days develop invasive mammary carcinomas

• chronic treatment with doxycycline results in rapid development of multiple mammary tumors with 100% penetrance and a latency of 6 weeks

• mammary tumors are invasive solid nodular carcinomas

• withdrawal of doxycycline from chronically induced mutants results in full regression of tumors to a nonpalpable state in 94% of mice; a decrease in cell proliferation and increase in cell apoptosis is seen during regression

• mice in which doxycycline withdrawal leads to complete regression of tumors show tumor recurrence in the absence of doxycycline after an average of 153 +/- 93 days off doxycycline

integument

mammary gland duct hyperplasia ( J:81083 )

• mice treated with doxycycline for 4 days exhibit hyperplastic abnormalities in the mammary ductal trees

increased mammary adenocarcinoma incidence ( J:81083 )

• mice treated with doxycycline for 21 days develop invasive mammary carcinomas

• chronic treatment with doxycycline results in rapid development of multiple mammary tumors with 100% penetrance and a latency of 6 weeks

• mammary tumors are invasive solid nodular carcinomas

• withdrawal of doxycycline from chronically induced mutants results in full regression of tumors to a nonpalpable state in 94% of mice; a decrease in cell proliferation and increase in cell apoptosis is seen during regression

• mice in which doxycycline withdrawal leads to complete regression of tumors show tumor recurrence in the absence of doxycycline after an average of 153 +/- 93 days off doxycycline

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:81083